Autologous and Allogeneic Cytotherapies for Large Knee (Osteo)Chondral Defects: Manufacturing Process Benchmarking and Parallel Functional Qualification

Autologous and Allogeneic Cytotherapies for Large Knee (Osteo)Chondral Defects: Manufacturing Process Benchmarking and Parallel Functional Qualification

Cytotherapies are often necessary for the management of symptomatic large knee (osteo)-chondral defects. While autologous chondrocyte implantation (ACI) has been clinically used for 30 years, allogeneic cells (clinical-grade FE002 primary chondroprogenitors) have been investigated in translational s...

Full description

Bibliographic Details
Main Authors: Virginie Philippe, Annick Jeannerat, Cédric Peneveyre, Sandra Jaccoud, Corinne Scaletta, Nathalie Hirt-Burri, Philippe Abdel-Sayed, Wassim Raffoul, Salim Darwiche, Lee Ann Applegate, Robin Martin, Alexis Laurent
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Pharmaceutics
Subjects:
allogeneic cytotherapies
autologous chondrocyte implantation
cartilage defect
chondrogenesis
cell therapy
FE002 primary chondroprogenitors
Online Access:https://www.mdpi.com/1999-4923/15/9/2333

Internet

https://www.mdpi.com/1999-4923/15/9/2333

Similar Items